COMMUNIQUÉS West-GlobeNewswire

Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing
21/07/2017
NOT FOR RELEAS E, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
21/07/2017
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis - First investigational targeted biologic in the European Union to receive [...]
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte
21/07/2017
Sanofi et Regeneron obtiennent un avis favorable du CHMP pour Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de l'adulte - Premier traitement biologique expérimental ciblé à obtenir [...]
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
21/07/2017
Recommendation based on largest trial in FLT3-mutated AML to date, showing 23% reduction in the risk of death with Rydapt treatment regimen[1] If approved, Rydapt would represent the first targeted treatment for newly [...]
uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
21/07/2017
-- Commercial-Scale Batches of AMT-060 Successfully Produced in Accordance with Good Manufacturing Practices in Lexington, MA Facility -- -- Manufacturing Process to be Leveraged in Huntington's Program, With Production [...]
LIDDS signs research agreement with major European pharma company
21/07/2017
LIDDS has entered into a research agreement with a major pharmaceutical company which has an exclusive option right to leverage the NanoZolid® technology for the development of an injectable, controlled-release [...]
Oriola Corporation's Half Year Financial Report January-June 2017
21/07/2017
Oriola Corporation Stock Exchange Release 21 July 2017 at 8.30 a.m. Oriola Corporation's Half Year Financial Report January - June 2017 Financial performance April-June 2017, continuing operations Invoicing decreased by [...]
Alligator Bioscience AB: Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
21/07/2017
Press release, July 21, 2017 Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy Strategic partnership will advance development of a novel [...]
EUROPEAN COMMISSION APPROVES MARKETING AUTHORISATION FOR VELTASSA®
21/07/2017
PRESS RELEASE This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging
20/07/2017
Collaborations result in development of Corning Valor(TM) Glass; drive significant U.S. investment and job creation The White House Office of American Innovation facilitates cross-industry technology collaboration and U [...]
Sanofi : Disclosure of trading in own shares
20/07/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
20/07/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
PHARMAGEST: major acquisition in the hospital information systems sector.
20/07/2017
Villers-lès-Nancy, 18 July 2017 - 7:00 p.m. (CET) PRESS RELEASE HOSPITAL INFORMATION SYSTEMS MAJOR ACQUISITION MALTA INFORMATIQUE, a PHARMAGEST Group subsidiary ( Euronext Paris #FR 0012882389 - PHA.PA ), announces the [...]
DarioHealth Announces Strategic Partnership with CCS Medical
24/07/2017
New initiative to provide diabetes patients across the U.S. with access to live monitoring and coaching via CCS Medical's LivingConnected program Caesarea, Israel and Dallas - July 24, 2017 - DarioHealth Corp. (NASDAQ: [...]
Auris Medical Completes Acquisition of AM-125 Assets
20/07/2017
Closing of asset transfer from Otifex Therapeutics Rights to additional preclinical and clinical data complement scope of data package Initiation of Phase 1 trial of AM-125 planned for the fourth quarter of 2017 ZUG, [...]
ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement
20/07/2017
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ON - July 20, 2017 - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN; OTCPK:ARFX.F; DB:23J) today [...]
LIDDS: LIDDS and Recipharm establish industrial manufacturing capabilities for a novel prostate cancer product
20/07/2017
LIDDS and Recipharm, the contract development and manufacturing organisation (CDMO), have together set up a manufacturing line for LIDDS' novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden. The [...]
Enzymatica AB: Continued sales growth and breakthrough order from STADA
20/07/2017
Enzymatica Interim report Jan-june2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are [...]
Basilea announces completion of the license agreement with Pfizer for antifungal Cresemba® for Europe, Russia, Turkey and Israel
20/07/2017
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba (isavuconazole), which was announced on [...]

Pages